Cambridge Healthtech Institute’s 3rd Annual

Antibodies Against Membrane Protein Targets

New Strategies and Technologies to Accelerate the Development of Biotherapeutics against Complex GPCR and Ion Channel Targets

7 November 2024

As pharma increasingly shifts its attention to biologics, more attention is being paid to developing biotherapeutics against membrane-bound targets—and the rapid adoption of ML and other advanced computational tools offers an exciting and expanded toolkit for R&D scientists working in this space. For 2024, the 3rd Annual PEGS Europe Antibodies Against Membrane Protein Targets conference explores various antigen strategies, emerging modalities, and promising avenues for expanding the druggable space via computational tools, novel target identification methods, and advanced understandings of protein signaling. The latest advancements in antibody discovery will be covered, including in silico approaches, transgenic models, and synthetic libraries.

Coverage will include, but is not limited to:

Antigen Strategies

  • Comparative evaluation of antigen format performance with different antibody platforms
  • mRNA applications for antibody discovery
  • Whole-cell panning, structural surfaceomics

Emerging Modalities for Membrane Protein Targets

  • Conjugates and multispecifics
  • Intracellular antibodies
  • Nanobodies and miniproteins
  • Targeted protein degraders

Expanding the Druggable Membrane Target Space

  • Computational target prediction
  • Exoproteome profiling to identify new ligands and potential drug candidates
  • ML modelling of disease biologies
  • New understandings of the biology of GPCR and ion-channel signaling
  • Phenotypic screening for target ID

Antibody Discovery

  • Advances and applications in in silico antibody discovery and design 
  • New and novel transgenic models
  • Next-generation synthetic librariesThe Future of Membrane Protein Discovery
  • Expanding understandings of the roles of autoantibodies in disease biology
  • Improved understandings of complex signaling cascades
  • Integrated ML models to simultaneously screen structure, signaling pathway, and MOA
  • Multiplexed experimentation; microfluidic-based screening
  • Next-generation predictions: affinity, epitope, cross-reactivity

The deadline for priority consideration is 29 March 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:

For more details on the conference, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 207-329-2964

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340